



RDTTM

RAPID DOSE THERAPEUTICS

CORPORATE PRESENTATION | MARCH 2019

CSE: DOSE

Disclaimer

This documentation is a presentation (the “Corporate Presentation”) of general background information about the current activities of Rapid Dose Therapeutics (RDT) Canada Inc. (“RDT”) as of March 7, 2019. It is information in a summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. This Corporate Presentation should be considered, with or without professional advice, when considering the business and prospects. This Corporate Presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for securities nor shall it or any part of it form the basis of or be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever. Recipients of this Corporate Presentation who are considering acquiring securities and assessing the business of RDT are reminded that any such assessment must not be made on the basis of the information contained in this Presentation but are referred to the entire body of publicly disclosed information regarding RDT.

Cautionary Note Regarding Forward-Looking Statements: Certain information in this document may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this Corporate Presentation that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often, although not always, identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of products using the QuickStrip™ product delivery method, express, as at the date of this Corporate Presentation, the plans, estimates, forecasts, projections, expectations or beliefs of RDT as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical and recreational marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally; income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on forward-looking statements. Forward-looking information contained in this Corporate Presentation are expressly qualified by this cautionary statement.

At a glance

Founded: May 3, 2017

Number of employees: 15

Publicly Traded: as of December 17, 2018

Ticker symbol: CSE:DOSE

Shares Issued & Outstanding: 75,121,327 shares

Warrants outstanding: 740,000 @ .50 cents (expiry as of May 17, 2019)

Share Fully Diluted: 75,861,327 (Escrowed shares 49,310,838)

Insider Ownership: 49.5%

Net Cash (as at December 31, 2018): \$3,955,841

Experienced management team

Mark Upsdell Chief Executive Officer

- Former Director, Global Strategy and Planning, CISCO
- Over 30 years experience providing strategic leadership in Fortune 500 companies within the technology sector
- Managed people, process, governance and tools — to enable global sales teams to drive a combined 11 billion in revenue.

Jason Lewis SVP, Business Development

- An entrepreneurial executive with +28 years of hands-on expertise within the healthcare and pharmaceutical sectors.
- Previously Director of International Marketing Apotex, and VP of Marketforce a subsidiary of GSW.

Lino Fera Chief Financial Officer

- CPA with +30 years experience in senior corporate financial roles.
- Former CFO of TSX listed company
- Previously CFO of Starshot Inc., Talc de Luzenac and Excel Health Services Inc.

Kristina Shea Marketing and Communications Director

- +25 years of experience in strategic leadership within marketing, branding, print/digital advertising, digital transformation and project management
- Worked with Fortune 500 companies — including consumer, financial and government sectors

Doug Hyland Manager Systems & Process

- CPA with +30 years
- Diverse strategic financial and business experience across multiple industries including manufacturing and distribution, financial services, technology, and the health industry.

Jason Bhola Director of Operations

- Global Sr. Pharmaceutical Operations Executive with +15 years of experience
- Expertise in manufacturing, packaging, quality, regulatory, supply chain, technology transfers, supplier alliance management, and project management.

Building a global brand

Game Changing Delivery

Rapid Dose Therapeutics, RDT, is a Canadian med-tech company providing a Managed Strip Service Program which enables proprietary drug delivery technologies designed to improve patient and consumer outcomes.

RDT provides a turnkey service program for product innovation, production, and consultation to the pharmaceutical, nutraceutical and cannabis industries. For more information, visit: rapid-dose.com

Mission

To create novel, convenient, enhanced rapid delivery therapeutics to improve healthcare outcomes for patients.



RDT verticals

RDT has three business divisions — delivering health and therapeutic applications.



Over the Counter (OTC) Nutraceuticals

- OTC product portfolio (NPN, Health Canada approved)
- QuickStrip™ Energy (Caffeine)
- QuickStrip™ B12
- QuickStrip™ Sleep (Melatonin)
- Other OTC products in the pipeline: QuickStrip™ Nicotine, Pain, Allergy, Vitamins
- Primary OTC targets for RDT are the large CDN US retail chains selling high volume consumer oriented products



Cannabis

- QuickStrip™ medical and recreational markets
- RDT licenses proprietary QuickStrip™ technology under a Managed Strip Services Contract (MSS) – this enables a **recurring revenue model**
- QuickStrip™ — The Quick, Convenient, Precise and Discreet™ smoke-free choice for consumers



Pharmaceutical

- Branded drug manufacturers seeking alternative delivery to expand or enhance products where rapid dosage or simplified delivery are important factors.
- Opportunity for branded products in mid-cycle, near patent expiry, or line extension.

Addressing the cannabis market

QuickStrip™

Anytime, Anywhere™

QuickStrip™ precisely delivers active Ingredients using an orally dissolvable strip to deliver the therapeutic dose **directly into the blood stream.**

**Quick,
Convenient,
Precise, Discreet™**

RDT's proprietary delivery system and trademarked brand QuickStrip™ transforms how pharmaceutical, nutraceuticals and cannabis are consumed.



The
Smoke-Free
Choice™
for cannabis
consumers




RDT licenses proprietary QuickStrip™ technology under a Managed Strip Services Contract (MSS) – this enables a **recurring revenue model**



RDT QuickStrip™ lifestyle nutraceuticals

Over the Counter (OTC) QuickStrip™ product portfolio
(NPN, Health Canada approved)

Distribution and e-commerce



ENERGY ⚡



VITAMIN B12 🍒



SLEEP 🌙

Company milestones



Definitive contract
signed with agreement
with **Aphria Canada**



Rapid Dose
Therapeutics Inc.
**listed on the
CSE:DOSE**



Definitive contract
signed with agreement
with **Aphria Germany**



Definitive contract
signed with Chemosis
for the **state of
California**



Definitive contract
signed with Flower One
for the state of **Nevada**



Definitive contract
signed with Chemosis
for the **territory of
Puerto Rico**

Company milestones



TOP 10 IN GROCERY

Top Ten New Product awarded by **Grocery Innovation Canada (GIC)** for non-food category



Five patents pending in **US** and **Canada**



Fourteen **trademarks** filed in Canada and the USA



QuickStrip™ available for retail in hotel kiosks in Las Vegas for Nutraceuticals: Energy, B12 & Sleep



Expansion of operations for a further **35,000 sq ft. production** for **QuickStrip technology** and **pipeline products**



Ten patents in process of being filed

Research & development



Researching polymer thin film technology for oil-based therapeutics delivery

UNLV
UNIVERSITY OF NEVADA LAS VEGAS



EEG & behavioural study underway with UNLV with QuickStrip™ delivery system

B12

Case Study of B12 for IBS with major medical institution in Canada



Case study delivering CBD with QuickStrip™ delivery system, uptake and potency with major US university



Development of methods for producing and purifying cannabinoids using natural, sustainable ingredients for use in both recreational and medicinal applications.


UNLV
UNIVERSITY OF NEVADA LAS VEGAS

Case study for related benefits underway with UNLV with QuickStrip™ delivery system

Cannabis recurring revenue business model



RDT licenses proprietary technology to licensed cannabis producers and growers globally — under a Managed Strip Service Agreement (MSSA)



**Currently five signed
(5-year) recurring revenue
contracts**

MSSA service-fee
for every strip produced
above minimum quantity

Financial impact of MSS Agreements



RDT continues to perform under these signed MSS agreements. With internal testing of production systems nearing completion, RDT has scheduled the **delivery of five QuickStrip™ production systems during the first quarter of FY2020** (FY2020 commences March 1, 2019) for installation and commissioning in RDT's customers' locations.

The signed MSS agreements provide:

- Initial **signing fees**, installation
- **Commissioning fees**
- Per unit production fees with **periodic minimums** and other revenues over their respective terms.

As a result of the signed MSS agreements, RDT has received, as of January 31, 2019, initial cash payments amounting to:

CDN\$1,137,656 and **173,556 common shares** of publicly traded companies with a **current market value** of approximately **CDN\$272,482**.

Canadian licensed manufacturer/reseller



Aphria secured
\$5.4MM
 private placement
 with RDT
7.2MM shares
 at **\$0.75**

- Research & development
- Clinical studies
- Manufacturing
- Marketing & sales

- High-quality genetics
- Expert Personnel
- Best practices
- Registered patient network
- Marketing & sales
- Global distribution channels

RDT Brand



Aphria-QuickStrip product distribution

Definitive agreement
 signed with RDT for
 exclusive **preferred**
global rights in Canada



Germany licensed manufacturing/reseller



Granted rights to license, manufacture, distribute and sell RDT's QuickStrip™ technology to the German cannabis market

- RDT and Aphria's agreement will support rapid global expansion of the QuickStrip™ brand and **accelerate QuickStrip™ consumer adoption into key European cannabis markets.**
- Aphria expects to produce and distribute CBD-only Quickstrips™ in Germany by Spring 2019.
- **Germany has a population of 82 million people — a population 2.5 times of Canada.**
- The BMO report below set the \$5 billion figure primarily based on an assumption that in seven years, 7.5% of sleep, anxiety and pain prescriptions in Germany will be replaced with cannabis — **opening up the cannabis market to approximately 26% of the overall German population.**¹

BMO's cannabis sector analysts forecast the German market could produce more than **\$5B in revenue for global cannabis producers.**¹

Reference: ¹ business.financialpost.com/cannabis/cannabis-producers-could-be-chasing-global-market-worth-194-billion-in-seven-years-bmo-report



Nevada manufacturing/reseller



Granted license to manufacture, distribute and sell QuickStrip™ delivery technology for the cannabis market in Nevada.

Nevada is one of the most lucrative cannabis markets in the United States, hosting 55 million tourists.

Nevada reported \$529.9MM in sales for all 2018 in cannabis sales and cannabis-related products.


- Flower One is the **largest cannabis cultivation greenhouse in Nevada** at 400,000 square feet.
- Flower One is the **largest cannabis processing and custom packaging facility in Nevada**, a 55,000 square foot operation.
- **Holds 9 licenses for medical and recreational cannabis cultivation and production in the state of Nevada.**
- Flower One's internal brand NLVO boasts a diverse **library of cannabis genetics which features over 50 unique strains** through its House Partner, NLV



Nevada cannabis market potential

Nevada's legal cannabis market
(US\$ in Millions)

Based on Colorado YoY Growth Rate



In Colorado

29.3%

3-year CAGR
Combined
Cannabis Sales
(2014 -2017)

In Nevada

\$529.9

2018 FY
Combined Sales
(1st Year)

*Includes both recreational and medical cannabis sales

Source: : State of Nevada, Department of Taxation and Statista 2018, Colorado Sales

California licensed manufacturer/reseller



- Established networks and **current retail operations underway in key markets in California.**
- Population of **California 39 million, larger than that of Canada**
- **QuickStrip™ is positioned for rapid growth with Chemesis** in the emerging US cannabis industry. Chemesis is a fully-compliant, fully licensed, first mover within California.



With nearly 40 million residents and more than a million medical marijuana patients, California's market represents about a third of the North American cannabis market.

Estimated cannabis California sales:



According to Arcview Market Research and BDS and Cowen & Co. analytics new report and Business Insider.



Puerto Rico licensed manufacturer/reseller



- Chemesis will continue to **expand the QuickStrip™ global footprint into the Puerto Rican and Latin American marketplace.**
- **Chemesis is currently retailing exclusive products in Puerto Rico which will include the QuickStrip™ brand to an available distribution of 600 dispensaries in both Puerto Rico and California**

Puerto Rico public health department anticipates registration of 100,000 registered patients by end of 2019.²

Legalized medical cannabis for qualifying health conditions in 2015, allows the use of medical cannabis derivatives.

Health Conditions include HIV, cancer, multiple sclerosis, migraines, anxiety, epilepsy, and other conditions.

² Reference: <http://www.salud.gov.pr/Documents/Cannabis/>



Thrive White Label Agreement (WLM)



RDT has signed a Memorandum of Understanding (MOU) with Thrive Cannabis to sell white label oral thin film strips with RDT's proprietary QuickStrip™ technology — using premium cannabis distillates provided by Thrive and by other RDT approved Licensed Producers in Canada.

The WLM agreement with Thrive will allow penetration into markets RDT would not otherwise have access to throughout Canada — amplifying reach and accelerating consumer adoption of the QuickStrip™ brand and delivery system.



This WLM agreement with Thrive will **maximize the use of the RDT's production capacity** — while enabling **Thrive, and contracted producers, to offer its customer base a smoke-free delivery alternative for cannabis distillates.**


RDT's **White Label Manufacturing (WLM)** contracts will be based on **monthly minimum recurring payments over a five (5) year period.**



Global footprint



Global market outlook



In the news



QuickStrip™ marketing strategy

Brand awareness, engagement and motivation to purchase
Educational videos

- Integrated media (TV, radio, podcasts, digital, print)
- QuickStrip™ sampling events, sponsorships
- Social media, influencers
- Featured interviews and articles in key publications



Appendix

Corporate video





Rapid Dose Therapeutics Corp.
1121 Walkers Line
Burlington ON L7N 2G4
P: 1 416.477.1052

For inquiries:

Ali Mahdavi
Managing Director
Spinnaker Capital Markets Inc.
am@spinnakercml.com
(416) 962-3300

CSE: DOSE